APO Research
Talk to an analyst

APO RESEARCH · REPORT

Lenalidomide Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Lenalidomide Drug Market Outlook and Growth Opportunities 2026

22 December 2025199 pages

Choose your research edition.

Industry ResearchLenalidomide Drug Industry Research Report 2026114 pages · $2,950 USDIndustry Growth & TrendsGlobal Lenalidomide Drug Industry Growth and Trends Forecast to 203278 pages · $3,450 USDMarket StructureGlobal Lenalidomide Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032175 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Lenalidomide Drug Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Lenalidomide Drug Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Lenalidomide Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Lenalidomide Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Lenalidomide Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Lenalidomide Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Lenalidomide Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Lenalidomide Drug market include Bristol Myers Squibb. among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Lenalidomide Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Lenalidomide Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Lenalidomide Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Lenalidomide Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Lenalidomide Drug Segment by Company

Bristol Myers Squibb

Lenalidomide Drug Segment by Type

5 mg Capsules

25 mg Capsules

15 mg Capsules

10 mg Capsules

Lenalidomide Drug Segment by Application

Multiple myeloma (MM)

Myelodysplastic syndromes (MDS)

Other

Lenalidomide Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Lenalidomide Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Lenalidomide Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Lenalidomide Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Lenalidomide Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Lenalidomide Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Lenalidomide Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Lenalidomide Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Lenalidomide Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Lenalidomide Drug industry.

Chapter 3: Detailed analysis of Lenalidomide Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Lenalidomide Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Lenalidomide Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Lenalidomide Drug Industry Trends Table 2. Lenalidomide Drug Industry Drivers Table 3. Lenalidomide Drug Industry Opportunities and Challenges Table 4. Lenalidomide Drug Industry Restraints Table 5. Global Lenalidomide Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Lenalidomide Drug Revenue Share by Company (2021-2026) Table 7. Global Lenalidomide Drug Sales Volume by Company (k units) & (2021-2026) Table 8. Global Lenalidomide Drug Sales Volume Share by Company (2021-2026) Table 9. Global Lenalidomide Drug Average Price (US$/unit) of Company (2021-2026) Table 10. Global Lenalidomide Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Lenalidomide Drug Key Company Manufacturing Base & Headquarters Table 12. Global Lenalidomide Drug Company, Product Type & Application Table 13. Global Lenalidomide Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Lenalidomide Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 5 mg Capsules Table 18. Significant Companies of 25 mg Capsules Table 19. Significant Companies of 15 mg Capsules Table 20. Significant Companies of 10 mg Capsules Table 21. Global Lenalidomide Drug Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 22. Global Lenalidomide Drug Sales Volume by Type (2021-2026) & (k units) Table 23. Global Lenalidomide Drug Sales Volume by Type (2027-2032) & (k units) Table 24. Global Lenalidomide Drug Sales Volume Share by Type (2021-2026) Table 25. Global Lenalidomide Drug Sales Volume Share by Type (2027-2032) Table 26. Global Lenalidomide Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Lenalidomide Drug Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Lenalidomide Drug Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Lenalidomide Drug Sales Value Share by Type (2021-2026) Table 30. Global Lenalidomide Drug Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Multiple myeloma (MM) Table 32. Significant Companies of Myelodysplastic syndromes (MDS) Table 33. Significant Companies of Other Table 34. Global Lenalidomide Drug Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 35. Global Lenalidomide Drug Sales Volume by Application (2021-2026) & (k units) Table 36. Global Lenalidomide Drug Sales Volume by Application (2027-2032) & (k units) Table 37. Global Lenalidomide Drug Sales Volume Share by Application (2021-2026) Table 38. Global Lenalidomide Drug Sales Volume Share by Application (2027-2032) Table 39. Global Lenalidomide Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Lenalidomide Drug Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Lenalidomide Drug Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Lenalidomide Drug Sales Value Share by Application (2021-2026) Table 43. Global Lenalidomide Drug Sales Value Share by Application (2027-2032) Table 44. Global Lenalidomide Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 45. Global Lenalidomide Drug Sales by Region (2021-2026) & (k units) Table 46. Global Lenalidomide Drug Sales Market Share by Region (2021-2026) Table 47. Global Lenalidomide Drug Sales by Region (2027-2032) & (k units) Table 48. Global Lenalidomide Drug Sales Market Share by Region (2027-2032) Table 49. Global Lenalidomide Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Lenalidomide Drug Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Lenalidomide Drug Sales Value Share by Region (2021-2026) Table 52. Global Lenalidomide Drug Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Lenalidomide Drug Sales Value Share by Region (2027-2032) Table 54. Global Lenalidomide Drug Market Average Price (US$/unit) by Region (2021-2026) Table 55. Global Lenalidomide Drug Market Average Price (US$/unit) by Region (2027-2032) Table 56. Global Lenalidomide Drug Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 57. Global Lenalidomide Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Lenalidomide Drug Sales by Country (2021-2026) & (k units) Table 59. Global Lenalidomide Drug Sales Market Share by Country (2021-2026) Table 60. Global Lenalidomide Drug Sales by Country (2027-2032) & (k units) Table 61. Global Lenalidomide Drug Sales Market Share by Country (2027-2032) Table 62. Global Lenalidomide Drug Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Lenalidomide Drug Sales Value Market Share by Country (2021-2026) Table 64. Global Lenalidomide Drug Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Lenalidomide Drug Sales Value Market Share by Country (2027-2032) Table 66. Bristol Myers Squibb Company Information Table 67. Bristol Myers Squibb Business Overview Table 68. Bristol Myers Squibb Lenalidomide Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 69. Bristol Myers Squibb Lenalidomide Drug Product Portfolio Table 70. Bristol Myers Squibb Recent Development Table 71. Key Raw Materials Table 72. Raw Materials Key Suppliers Table 73. Lenalidomide Drug Distributors List Table 74. Lenalidomide Drug Customers List Table 75. Research Programs/Design for This Report Table 76. Authors List of This Report Table 77. Secondary Sources Table 78. Primary Sources List of Figures Figure 1. Lenalidomide Drug Product Image Figure 2. Global Lenalidomide Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Lenalidomide Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Lenalidomide Drug Sales (2021-2032) & (k units) Figure 5. Global Lenalidomide Drug Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Lenalidomide Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 5 mg Capsules Image Figure 10. 25 mg Capsules Image Figure 11. 15 mg Capsules Image Figure 12. 10 mg Capsules Image Figure 13. Global Lenalidomide Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Lenalidomide Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Lenalidomide Drug Sales Volume Share by Type (2021-2032) Figure 16. Global Lenalidomide Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Lenalidomide Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Lenalidomide Drug Sales Value Share by Type (2021-2032) Figure 19. Multiple myeloma (MM) Image Figure 20. Myelodysplastic syndromes (MDS) Image Figure 21. Other Image Figure 22. Global Lenalidomide Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global Lenalidomide Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Lenalidomide Drug Sales Volume Share by Application (2021-2032) Figure 25. Global Lenalidomide Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Lenalidomide Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Lenalidomide Drug Sales Value Share by Application (2021-2032) Figure 28. Global Lenalidomide Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 29. Global Lenalidomide Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Lenalidomide Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Lenalidomide Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Lenalidomide Drug Sales Value (2021-2032) & (US$ Million) Figure 33. North America Lenalidomide Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Lenalidomide Drug Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Lenalidomide Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Lenalidomide Drug Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Lenalidomide Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Lenalidomide Drug Sales Value (2021-2032) & (US$ Million) Figure 39. South America Lenalidomide Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Lenalidomide Drug Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Lenalidomide Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Lenalidomide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Lenalidomide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Lenalidomide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Lenalidomide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Lenalidomide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Lenalidomide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Lenalidomide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Lenalidomide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Lenalidomide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Lenalidomide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Lenalidomide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Lenalidomide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Lenalidomide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Lenalidomide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Lenalidomide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Lenalidomide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Lenalidomide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Lenalidomide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Lenalidomide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Lenalidomide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Lenalidomide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Lenalidomide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Lenalidomide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Lenalidomide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Lenalidomide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Lenalidomide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Lenalidomide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Lenalidomide Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Lenalidomide Drug Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Lenalidomide Drug Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • 5 mg Capsules
  • 25 mg Capsules
  • 15 mg Capsules
  • 10 mg Capsules
Applications
  • Multiple myeloma (MM)
  • Myelodysplastic syndromes (MDS)
  • Other
Companies covered
  • Bristol Myers Squibb

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Lenalidomide Drug Sales Value (2021-2032)
  4. 1.2.2 Global Lenalidomide Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Lenalidomide Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Lenalidomide Drug Market Dynamics
  1. 2.1 Lenalidomide Drug Industry Trends
  2. 2.2 Lenalidomide Drug Industry Drivers
  3. 2.3 Lenalidomide Drug Industry Opportunities and Challenges
  4. 2.4 Lenalidomide Drug Industry Restraints
3 Lenalidomide Drug Market by Company
  1. 3.1 Global Lenalidomide Drug Company Revenue Ranking in 2025
  2. 3.2 Global Lenalidomide Drug Revenue by Company (2021-2026)
  3. 3.3 Global Lenalidomide Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Lenalidomide Drug Average Price by Company (2021-2026)
  5. 3.5 Global Lenalidomide Drug Company Ranking (2024-2026)
  6. 3.6 Global Lenalidomide Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Lenalidomide Drug Company Product Type and Application
  8. 3.8 Global Lenalidomide Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Lenalidomide Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Lenalidomide Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Lenalidomide Drug Market by Type
  1. 4.1 Lenalidomide Drug Type Introduction
  2. 4.1.1 5 mg Capsules
  3. 4.1.2 25 mg Capsules
  4. 4.1.3 15 mg Capsules
  5. 4.1.4 10 mg Capsules
  6. 4.2 Global Lenalidomide Drug Sales Volume by Type
  7. 4.2.1 Global Lenalidomide Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Lenalidomide Drug Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Lenalidomide Drug Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Lenalidomide Drug Sales Value by Type
  11. 4.3.1 Global Lenalidomide Drug Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Lenalidomide Drug Sales Value by Type (2021-2032)
  13. 4.3.3 Global Lenalidomide Drug Sales Value Share by Type (2021-2032)
5 Lenalidomide Drug Market by Application
  1. 5.1 Lenalidomide Drug Application Introduction
  2. 5.1.1 Multiple myeloma (MM)
  3. 5.1.2 Myelodysplastic syndromes (MDS)
  4. 5.1.3 Other
  5. 5.2 Global Lenalidomide Drug Sales Volume by Application
  6. 5.2.1 Global Lenalidomide Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Lenalidomide Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Lenalidomide Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Lenalidomide Drug Sales Value by Application
  10. 5.3.1 Global Lenalidomide Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Lenalidomide Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Lenalidomide Drug Sales Value Share by Application (2021-2032)
6 Lenalidomide Drug Regional Sales and Value Analysis
  1. 6.1 Global Lenalidomide Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Lenalidomide Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Lenalidomide Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Lenalidomide Drug Sales by Region (2027-2032)
  5. 6.3 Global Lenalidomide Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Lenalidomide Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Lenalidomide Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Lenalidomide Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Lenalidomide Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Lenalidomide Drug Sales Value (2021-2032)
  12. 6.6.2 North America Lenalidomide Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Lenalidomide Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Lenalidomide Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Lenalidomide Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Lenalidomide Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Lenalidomide Drug Sales Value (2021-2032)
  21. 6.9.2 South America Lenalidomide Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Lenalidomide Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Lenalidomide Drug Sales Value Share by Country, 2025 VS 2032
7 Lenalidomide Drug Country-level Sales and Value Analysis
  1. 7.1 Global Lenalidomide Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Lenalidomide Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Lenalidomide Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Lenalidomide Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Lenalidomide Drug Sales by Country (2027-2032)
  6. 7.4 Global Lenalidomide Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Lenalidomide Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Lenalidomide Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Lenalidomide Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Lenalidomide Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Lenalidomide Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Lenalidomide Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Lenalidomide Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Lenalidomide Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Lenalidomide Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Lenalidomide Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Lenalidomide Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Lenalidomide Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Lenalidomide Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Lenalidomide Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Lenalidomide Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Lenalidomide Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Lenalidomide Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Lenalidomide Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Lenalidomide Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Lenalidomide Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Lenalidomide Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Lenalidomide Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Lenalidomide Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Lenalidomide Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Lenalidomide Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Lenalidomide Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Lenalidomide Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Lenalidomide Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Lenalidomide Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Lenalidomide Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Lenalidomide Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Lenalidomide Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Bristol Myers Squibb
  2. 8.1.1 Bristol Myers Squibb Company Information
  3. 8.1.2 Bristol Myers Squibb Business Overview
  4. 8.1.3 Bristol Myers Squibb Lenalidomide Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Bristol Myers Squibb Lenalidomide Drug Product Portfolio
  6. 8.1.5 Bristol Myers Squibb Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Lenalidomide Drug Value Chain Analysis
  2. 9.1.1 Lenalidomide Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Lenalidomide Drug Sales Mode & Process
  6. 9.2 Lenalidomide Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Lenalidomide Drug Distributors
  9. 9.2.3 Lenalidomide Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst